Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mirena

Phase 2Small molecule

Mirena is one of 17 small molecule programs targeting Hyperplasia. It is currently in Phase 2.

1

Indications

14

Total Trials

1

Active Trials

16

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaNot yet recruiting

HyperplasiaPhase 2

Not yet recruiting

Competition

Competitive Landscape

17 competitors in Hyperplasia

#DrugCompanyPhaseTrials

Nolvadex

Lialda

Megace

Bristol-Myers Squibb

Propecia

OOrganon and Co

Femara

Ativan

BBausch Health Americas, Inc.

Gnrh Ant

Methoxyflurane - Penthrox

UUniversity of Manitoba

Percocet Pill

UUniversity of Manitoba

Mounjaro

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Not yet recruiting

Hyperplasia

NCT06073184

Clinical

Trials by Indication[1]

Contraception4 trials

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Terminated·MMedicines360·Phase 3·NCT00995150·1,910 enrolled

Duration of Use of Highly Effective Reversible Contraception

Completed· Bayer logo

Bayer··NCT02414919·13,880 enrolled

HR-QoL and Sexuality in Mirena Inserted Contraception Users

Completed· Bayer logo

Bayer·Phase 4·NCT00498784·141 enrolled

Show 1 more trial

Long-Acting Reversible Contraception

Completed·FFHI 360·Phase 4·NCT01299116·916 enrolled

Menopause1 trial

Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression

Completed·UUniversity of Colorado, Denver·N/A·NCT01613131·39 enrolled

Bleeding1 trial

Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)

Completed· Bayer logo

Bayer·Phase 4·NCT01295294·187 enrolled

Trial1 trial

Scandinavian Mirena Insertion Nulliparous Trial.

Completed· Bayer logo

Bayer··NCT00798980·224 enrolled

Hyperplasia1 trial

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

Not yet recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06073184·71 enrolled

6 more indications

Atypical Endometrial Hyperplasia1 trial

A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore

Unknown status·KKK Women's and Children's Hospital·Phase 2·NCT05492487·60 enrolled

Heavy Menstrual Bleeding1 trial

Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding

Completed·UUteron Pharma S.A.·Phase 3·NCT01695902·280 enrolled

Systemic1 trial

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

Terminated·TThomas Cherpes, DVM, MD··NCT01750476·7 enrolled

Cohort Study1 trial

Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study

Completed·UUniversity of Colorado, Denver··NCT02067663·123 enrolled

Women1 trial

To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development

Terminated· Bayer logo

Bayer·Phase 2·NCT02490774·174 enrolled

Unspecified1 trial

Mirena Efficiency and Tolerability During the First Year of Use

Completed· Bayer logo

Bayer·Phase 4·NCT00696202·199 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Mirena. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirena compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirena. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bayer

Related News